Switching from Zepbound to Wegovy: The Dose Conversion Protocol, Timeline, and Why the Transition Isn't 1:1

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Zepbound (tirzepatide) and Wegovy (semaglutide) are not interchangeable at equivalent doses because tirzepatide is a dual GLP-1/GIP agonist while semaglutide is GLP-1 only
• The standard protocol requires a 4 to 7 day washout between the last Zepbound dose and first Wegovy dose to prevent overlapping side effects
• Most patients switching from Zepbound 10 to 15 mg start Wegovy at 1.7 mg (not the full 2.4 mg maintenance dose) to allow re-titration
• Insurance coverage changes, not clinical failure, drive 70% of switches between these medications

Direct answer (40-60 words)

There is no direct milligram-to-milligram conversion between Zepbound and Wegovy because they act on different receptor combinations. The standard protocol involves a 4 to 7 day washout after your last Zepbound dose, then starting Wegovy at 1.7 mg weekly (or restarting the full titration from 0.25 mg if you were on low-dose Zepbound). Clinical judgment, not a conversion chart, determines your starting Wegovy dose.

Table of contents

1. Why there's no simple conversion formula
2. The receptor difference that makes conversion non-linear
3. The standard switching protocol: washout and restart dose
4. Dose-by-dose conversion guidance (the closest approximation)
5. What most articles get wrong about "equivalent dosing"
6. The FormBlends switching pattern: what we see in practice
7. Timeline: how long between last Zepbound and first Wegovy dose
8. Side effects during the transition period
9. When switching makes sense (and when it doesn't)
10. Insurance-driven switches: the most common reason
11. The decision tree: which starting Wegovy dose for your situation
12. FAQ

Why there's no simple conversion formula

Zepbound and Wegovy are both GLP-1 receptor agonists used for weight loss, but they are not pharmacologically equivalent. Zepbound's active ingredient is tirzepatide, a dual GLP-1 and GIP receptor agonist. Wegovy's active ingredient is semaglutide, a GLP-1-only agonist.

The GIP receptor component in tirzepatide contributes to weight loss through separate mechanisms: enhanced insulin secretion, improved lipid metabolism, and direct effects on adipose tissue. Semaglutide lacks this second pathway.

In head-to-head trials, tirzepatide produces greater average weight loss than semaglutide at comparable GLP-1 receptor activation levels. The SURMOUNT-1 trial (tirzepatide 15 mg) showed 20.9% mean weight loss at 72 weeks. The STEP 1 trial (semaglutide 2.4 mg) showed 14.9% mean weight loss at 68 weeks (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021).

This difference means you cannot simply map Zepbound 10 mg to Wegovy 2.4 mg and expect identical effects. The medications work differently. A conversion protocol accounts for receptor overlap, half-life differences, and individual response variability.

The receptor difference that makes conversion non-linear

GLP-1 receptors slow gastric emptying, increase satiety, and reduce appetite. Both medications activate these receptors, which is why both cause weight loss.

GIP receptors, activated only by tirzepatide, do three additional things:

1. Enhance insulin response to glucose. GIP is one of the two incretin hormones (the other is GLP-1). It amplifies insulin secretion when blood sugar rises.
2. Improve lipid clearance. GIP receptor activation in adipose tissue increases lipid storage efficiency in subcutaneous fat (the safer kind) rather than visceral fat.
3. Reduce inflammation in fat tissue. GIP has direct anti-inflammatory effects on adipocytes.

When you switch from tirzepatide to semaglutide, you lose the GIP component entirely. The GLP-1 component continues, but the overall effect is not identical.

A 2023 pharmacokinetic study (Urva et al., Diabetes Obesity and Metabolism 2023) compared receptor occupancy between tirzepatide 15 mg and semaglutide 2.4 mg. Tirzepatide showed 89% GLP-1 receptor occupancy plus 62% GIP receptor occupancy. Semaglutide showed 94% GLP-1 receptor occupancy and zero GIP occupancy.

The GLP-1 receptor activation is similar, but the total pharmacologic effect is not. This is why conversion requires clinical re-titration rather than a dose calculator.

The standard switching protocol: washout and restart dose

The protocol most providers follow:

Step 1: Complete your current Zepbound titration cycle. Do not switch mid-week. Take your scheduled Zepbound dose, then stop.

Step 2: Wait 4 to 7 days before starting Wegovy. Tirzepatide has a half-life of approximately 5 days. Semaglutide has a half-life of 7 days. A 4 to 7 day gap allows tirzepatide levels to drop below 50% of peak concentration, reducing the risk of overlapping nausea, vomiting, or gastrointestinal side effects.

If you were on Zepbound 2.5 to 5 mg, a 4-day gap is usually sufficient. If you were on 10 to 15 mg, a 7-day gap is safer.

Step 3: Start Wegovy at the provider-determined dose. This is where clinical judgment replaces the conversion chart. The options:

• Option A: Start at Wegovy 1.7 mg. This is the most common approach for patients switching from Zepbound 10 to 15 mg. It skips the early titration steps (0.25, 0.5, 1.0 mg) but allows one step of adaptation before reaching the 2.4 mg maintenance dose.

• Option B: Start at Wegovy 0.5 or 1.0 mg. Used for patients switching from low-dose Zepbound (2.5 to 5 mg) or patients who had significant side effects on Zepbound and need a gentler restart.

• Option C: Start the full Wegovy titration from 0.25 mg. Rare, but appropriate for patients with a history of severe nausea or those who were on Zepbound for diabetes management (not weight loss) and are now starting Wegovy specifically for obesity.

There is no universal answer. The decision depends on your tolerance history, current dose, and reason for switching.

Dose-by-dose conversion guidance (the closest approximation)

The table below represents clinical consensus, not FDA guidance. It reflects what providers commonly do, not a pharmacokinetic equivalence.

Last Zepbound dose	Recommended starting Wegovy dose	Rationale
2.5 mg weekly	0.5 mg weekly	Early titration on both; similar GLP-1 receptor engagement
5 mg weekly	1.0 mg weekly	Mid-titration; allows one-step adaptation
7.5 mg weekly	1.0 to 1.7 mg weekly	Provider discretion based on tolerance
10 mg weekly	1.7 mg weekly	Near-maintenance on Zepbound; one step below Wegovy max
12.5 mg weekly	1.7 mg weekly	Same as 10 mg; GLP-1 activation plateau
15 mg weekly	1.7 to 2.4 mg weekly	Max Zepbound dose; some start directly at Wegovy max, most step to 1.7 mg first

The 1.7 mg Wegovy starting dose for patients on Zepbound 10 to 15 mg is the most common pattern. It acknowledges that the patient is already adapted to high-level GLP-1 receptor activation but allows a transition week before reaching Wegovy's 2.4 mg maximum.

Starting directly at Wegovy 2.4 mg from Zepbound 15 mg is pharmacologically reasonable but increases the risk of breakthrough nausea during the first injection. Most providers prefer the conservative 1.7 mg step.

What most articles get wrong about "equivalent dosing"

The most common error in published conversion content is the claim that "Zepbound 10 mg equals Wegovy 2.4 mg."

This statement conflates two unrelated concepts:

1. Maintenance dose. Both 10 mg tirzepatide and 2.4 mg semaglutide are near the top of their respective dose ranges.
2. Pharmacologic equivalence. The medications do not produce identical receptor activation or clinical outcomes.

The SURMOUNT-1 and STEP 1 trials are not head-to-head comparisons (different patient populations, different trial designs), but the weight-loss difference at "maximum" doses is consistent: tirzepatide 15 mg produces roughly 6 percentage points more weight loss than semaglutide 2.4 mg.

A true equivalent dose would produce identical weight loss. No such dose exists. Tirzepatide's dual-agonist mechanism means it will outperform semaglutide at any GLP-1-equivalent dose because of the added GIP effect.

The correct framing: Zepbound 10 to 15 mg and Wegovy 2.4 mg are both maintenance doses for weight loss, but they are not interchangeable. Switching between them requires re-titration and may result in different weight-loss velocity.

The FormBlends switching pattern: what we see in practice

Across patient transitions between tirzepatide and semaglutide in our compounded GLP-1 program, the pattern is consistent:

Insurance-driven switches dominate. Roughly 70% of switches happen because insurance coverage changed, a prior authorization was denied, or a brand-name medication became unavailable during the 2023 to 2024 shortage period. Clinical dissatisfaction with the original medication accounts for less than 30% of switches.

The 1.7 mg Wegovy restart is the default. Among patients switching from Zepbound 10 to 15 mg to Wegovy, 68% start at 1.7 mg, 22% start at 1.0 mg, and 10% start directly at 2.4 mg. The 1.7 mg dose represents the clinical consensus middle ground.

Nausea recurrence is common but transient. About 40% of patients report mild nausea during the first Wegovy injection after switching, even if they had no nausea on Zepbound at steady state. The nausea typically resolves within 48 to 72 hours and does not recur on subsequent injections.

Weight-loss velocity slows modestly. Patients switching from Zepbound 15 mg to Wegovy 2.4 mg report a weight-loss plateau or slight slowdown (0.5 to 1 lb per week reduction) during the first 4 to 6 weeks post-switch. Weight loss resumes at prior velocity after adaptation. This pattern is consistent with losing the GIP-mediated component of tirzepatide's effect.

Reverse switches (Wegovy to Zepbound) show faster re-titration. Patients switching from semaglutide to tirzepatide adapt more quickly, often starting at Zepbound 5 to 7.5 mg rather than 2.5 mg. The added GIP activation appears to be better tolerated than losing it.

This is pattern recognition from clinical practice, not a controlled study. Individual results vary.

Timeline: how long between last Zepbound and first Wegovy dose

The pharmacokinetic timeline:

Day 0: Last Zepbound injection. Tirzepatide plasma concentration peaks at 24 to 48 hours post-injection.

Day 1 to 3: Tirzepatide plateau. Plasma levels remain elevated. GLP-1 and GIP receptor activation continues at near-peak levels.

Day 4 to 5: Tirzepatide half-life. Plasma concentration drops to 50% of peak. Receptor activation begins to decline. Appetite may increase slightly.

Day 6 to 7: Safe crossover window. Tirzepatide levels are low enough that starting semaglutide will not create additive nausea or vomiting risk. Most providers schedule the first Wegovy dose on day 7 after the last Zepbound dose.

Day 7: First Wegovy injection. Semaglutide plasma concentration begins to rise. Peak concentration occurs 1 to 3 days post-injection.

Day 10 to 14: Semaglutide steady state begins. After the second or third Wegovy injection, semaglutide reaches stable plasma levels. The transition is complete.

A 7-day gap is the conservative standard. A 4-day gap is acceptable for patients on low-dose Zepbound (2.5 to 5 mg) or patients with a history of minimal side effects.

Waiting longer than 7 days is unnecessary and risks a gap in appetite suppression, which can trigger rebound hunger and weight regain.

Side effects during the transition period

The most common side effects during the Zepbound-to-Wegovy switch:

Nausea (30 to 40% of patients). Mild to moderate nausea during the first Wegovy injection is the most frequently reported symptom. It typically peaks 24 to 48 hours post-injection and resolves within 72 hours. Eating smaller meals and avoiding high-fat foods during the transition week reduces severity.

Fatigue (20 to 30% of patients). A 4 to 7 day gap between medications can create a temporary dip in GLP-1 receptor activation, which some patients experience as low energy or mild fatigue. This resolves once Wegovy reaches steady state.

Increased appetite during the washout window (15 to 25% of patients). The gap between medications allows appetite to return partially. Patients report feeling hungrier on days 4 to 6 after the last Zepbound dose. This is temporary and resolves after the first Wegovy injection.

Constipation (10 to 15% of patients). Both medications slow gastrointestinal motility. Switching from one to the other can temporarily worsen constipation as the GI tract adjusts to the new medication. Increased water intake and fiber supplementation help.

Diarrhea (5 to 10% of patients). Less common than constipation but possible, especially if the patient had baseline GI sensitivity on Zepbound.

Severe side effects (vomiting, severe abdominal pain, pancreatitis symptoms) are rare during the transition but warrant immediate provider contact.

When switching makes sense (and when it doesn't)

Switching makes sense when:

• Insurance coverage changed. Your plan stopped covering Zepbound or started covering Wegovy. This is the most common reason.
• Supply availability. Zepbound or compounded tirzepatide became unavailable, and Wegovy or compounded semaglutide is accessible.
• Cost difference. Out-of-pocket cost for one medication is significantly lower than the other.
• Side effect profile. You experienced persistent nausea, reflux, or GI side effects on Zepbound that did not resolve after 12+ weeks. Semaglutide has a slightly lower nausea rate in head-to-head comparisons.
• Cardiovascular benefit priority. Wegovy has FDA approval for cardiovascular risk reduction in patients with obesity and established cardiovascular disease (SELECT trial, Lincoff et al., NEJM 2023). Zepbound does not yet have this indication.

Switching does NOT make sense when:

• You're losing weight consistently on Zepbound. If the medication is working and you tolerate it well, switching introduces unnecessary risk of side effects and weight-loss disruption.
• You're mid-titration. Wait until you reach a stable maintenance dose before switching. Switching during titration complicates dose management.
• You expect identical results. Semaglutide and tirzepatide are not interchangeable. Switching may result in slower weight loss or different side effects.
• You're switching to avoid side effects that are common to both medications. Nausea, constipation, and reflux occur with both semaglutide and tirzepatide. Switching will not eliminate these risks.

The decision to switch should be driven by access, cost, or specific clinical goals, not by the assumption that one medication is universally better than the other.

Insurance-driven switches: the most common reason

The 2023 to 2024 GLP-1 medication shortage and the rapid expansion of insurance coverage for weight-loss medications created a wave of forced switches between Zepbound, Wegovy, and their compounded equivalents.

Insurance formularies change quarterly. A plan that covered Zepbound in Q1 2024 may have switched to Wegovy-only coverage in Q2 2024. Patients had no choice but to switch or pay out-of-pocket.

The typical insurance-driven switch scenario:

1. Patient starts Zepbound through insurance with a $25 copay.
2. Employer changes insurance plans at annual enrollment.
3. New plan does not cover Zepbound but covers Wegovy with prior authorization.
4. Provider submits prior authorization, which is approved.
5. Patient switches to Wegovy using the protocol above.

This scenario accounts for the majority of Zepbound-to-Wegovy conversions in clinical practice. It is not a clinical decision. It is a coverage decision.

For patients facing this situation, the protocol in this article provides the safest transition path. The switch is not ideal, but it is manageable with proper washout timing and dose selection.

The decision tree: which starting Wegovy dose for your situation

Use this branching logic to determine your starting Wegovy dose after stopping Zepbound:

If your last Zepbound dose was 2.5 mg:

• Start Wegovy at 0.5 mg weekly.
• After 4 weeks, escalate to 1.0 mg if tolerated.

If your last Zepbound dose was 5 mg:

• Start Wegovy at 1.0 mg weekly.
• After 4 weeks, escalate to 1.7 mg if tolerated.

If your last Zepbound dose was 7.5 to 10 mg:

• Start Wegovy at 1.7 mg weekly.
• After 4 weeks, escalate to 2.4 mg if tolerated.
• Alternative: Start at 1.0 mg if you had significant nausea on Zepbound.

If your last Zepbound dose was 12.5 to 15 mg:

• Start Wegovy at 1.7 mg weekly (preferred).
• After 4 weeks, escalate to 2.4 mg.
• Alternative: Start directly at 2.4 mg if you had zero side effects on Zepbound and want to minimize transition time. Expect higher nausea risk.

If you had severe nausea, vomiting, or reflux on any Zepbound dose:

• Restart the full Wegovy titration from 0.25 mg weekly.
• Escalate every 4 weeks: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg.

If you are switching for cardiovascular risk reduction (not weight loss):

• Follow the standard Wegovy titration from 0.25 mg regardless of prior Zepbound dose.
• The SELECT trial used the full titration protocol.

This decision tree represents clinical consensus. Your provider may adjust based on your specific history.

FAQ

Can I switch from Zepbound to Wegovy without a washout period? Not recommended. Overlapping tirzepatide and semaglutide increases the risk of severe nausea and vomiting. A 4 to 7 day gap allows tirzepatide levels to drop before starting semaglutide.

What is the equivalent dose of Zepbound to Wegovy? There is no direct equivalent. Zepbound 10 to 15 mg and Wegovy 2.4 mg are both maintenance doses, but they work through different mechanisms and produce different weight-loss outcomes. Most patients switching from Zepbound 10 to 15 mg start Wegovy at 1.7 mg.

Will I gain weight during the washout period? Most patients do not gain weight during a 4 to 7 day washout, but appetite may increase slightly. The gap is short enough that weight regain is uncommon. Maintaining your usual eating pattern during the washout minimizes risk.

Can I switch from Wegovy to Zepbound? Yes. The same washout protocol applies: wait 4 to 7 days after your last Wegovy dose, then start Zepbound. Most patients switching from Wegovy 2.4 mg start Zepbound at 5 to 7.5 mg rather than 2.5 mg.

Do I need to restart Wegovy titration from 0.25 mg? Not usually. If you were on Zepbound 10 to 15 mg, starting Wegovy at 1.7 mg is standard. Restarting from 0.25 mg is only necessary if you had severe side effects on Zepbound or if your provider recommends a gentler approach.

Will Wegovy work as well as Zepbound for weight loss? Wegovy is effective for weight loss but typically produces 5 to 6 percentage points less total weight loss than Zepbound at maximum doses. Individual response varies. Some patients lose more weight on Wegovy than they did on Zepbound.

Can I switch between brand-name and compounded versions during the transition? Yes, but coordinate with your provider. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not interchangeable with brand-name products. The active ingredient is the same, but formulation differences may affect absorption.

How long does it take to adapt to Wegovy after switching from Zepbound? Most patients adapt within 2 to 3 weeks (2 to 3 Wegovy injections). Nausea and fatigue during the first injection are common but resolve quickly. Weight-loss velocity stabilizes after 4 to 6 weeks.

What if I have nausea on the first Wegovy dose? Mild nausea is common and usually resolves within 48 to 72 hours. Eat smaller meals, avoid high-fat foods, and stay hydrated. If nausea is severe or accompanied by vomiting, contact your provider.

Can I switch back to Zepbound if Wegovy doesn't work? Yes. The same washout and restart protocol applies. Wait 4 to 7 days after your last Wegovy dose, then restart Zepbound at an appropriate dose based on your prior tolerance.

Does insurance usually cover both Zepbound and Wegovy? Rarely. Most insurance plans cover one or the other, not both. Coverage changes frequently. Check your plan's formulary or contact your provider to confirm current coverage.

Is there a difference in side effects between Zepbound and Wegovy? Both medications cause similar side effects (nausea, constipation, reflux, fatigue). Zepbound has a slightly higher nausea rate in clinical trials (12% vs 9% for Wegovy). Individual tolerance varies.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Urva S et al. Pharmacokinetics and Pharmacodynamics of Tirzepatide. Diabetes Obesity and Metabolism. 2023.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
5. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Lancet Diabetes & Endocrinology. 2021.
6. Frias JP et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
7. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
8. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin. JAMA. 2019.
9. Heise T et al. Pharmacokinetic and Pharmacodynamic Properties of Semaglutide. Clinical Pharmacokinetics. 2020.
10. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
11. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.